$BCLI
Brainstorm Cell Therapeutics Inc

2019 Q2 Form 10-Q Financial Statement

#000114420419025310 Filed on May 10, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.300M $1.470M $1.580M
YoY Change -19.25% 10.53% 18.8%
% of Gross Profit
Research & Development $3.554M $3.456M $3.860M
YoY Change 140.14% 253.74% -345.86%
% of Gross Profit
Depreciation & Amortization $33.00K $44.00K $20.00K
YoY Change 6.45% 76.0% -33.33%
% of Gross Profit
Operating Expenses $3.554M $3.456M $5.440M
YoY Change 15.02% 253.74% -2366.67%
Operating Profit -$4.857M -$4.928M
YoY Change 57.34% 113.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$40.00K -$100.0K $50.00K
YoY Change -1100.0% 25.0%
Pretax Income -$4.900M -$5.030M -$5.380M
YoY Change 58.58% 118.7% -2021.43%
Income Tax
% Of Pretax Income
Net Earnings -$4.900M -$5.027M -$5.380M
YoY Change 58.58% 118.76% -2021.43%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$225.8K -$240.4K -$259.5K
COMMON SHARES
Basic Shares Outstanding 21.70M 29.49M 20.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.700M $6.230M $7.060M
YoY Change -84.52% 11.05% -9.02%
Cash & Equivalents $1.126M $3.238M $942.0K
Short-Term Investments $1.580M $2.990M $6.120M
Other Short-Term Assets $920.0K $1.230M $1.190M
YoY Change -20.69% 7.89% -0.83%
Inventory
Prepaid Expenses $1.103M $1.103M
Receivables $1.920M $800.0K $2.010M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $5.540M $8.257M $10.27M
YoY Change -71.68% 4.92% 6.72%
LONG-TERM ASSETS
Property, Plant & Equipment $3.300M $611.0K $651.0K
YoY Change 450.0% 49.02% 66.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $30.00K $3.594M $958.0K
YoY Change -96.51% 215.26% -46.78%
Total Long-Term Assets $3.320M $3.594M $958.0K
YoY Change 127.4% 133.38% -46.78%
TOTAL ASSETS
Total Short-Term Assets $5.540M $8.257M $10.27M
Total Long-Term Assets $3.320M $3.594M $958.0K
Total Assets $8.860M $11.85M $11.23M
YoY Change -57.85% 25.94% -1.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.770M $5.029M $4.548M
YoY Change 109.81% 54.26% 219.38%
Accrued Expenses $1.020M $2.246M $1.042M
YoY Change -30.61% 410.45% 27.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.54M $8.480M $6.212M
YoY Change 29.33% 51.97% 12.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.840M $3.050M
YoY Change
Total Long-Term Liabilities $2.840M $3.045M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.54M $8.480M $6.212M
Total Long-Term Liabilities $2.840M $3.045M $0.00
Total Liabilities $13.38M $11.53M $6.212M
YoY Change 64.17% 106.58% 12.07%
SHAREHOLDERS EQUITY
Retained Earnings -$99.05M -$94.02M
YoY Change 17.42%
Common Stock $98.34M $94.63M
YoY Change 10.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.516M $326.0K $5.016M
YoY Change
Total Liabilities & Shareholders Equity $8.860M $11.85M $11.23M
YoY Change -57.85% 25.94% -1.71%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$4.900M -$5.027M -$5.380M
YoY Change 58.58% 118.76% -2021.43%
Depreciation, Depletion And Amortization $33.00K $44.00K $20.00K
YoY Change 6.45% 76.0% -33.33%
Cash From Operating Activities -$3.508M -$835.0K -$3.720M
YoY Change -6478.18% -60.72% 26.96%
INVESTING ACTIVITIES
Capital Expenditures $21.00K $4.000K -$110.0K
YoY Change -90.23% -91.11% 83.33%
Acquisitions
YoY Change
Other Investing Activities $1.410M $3.140M $4.080M
YoY Change -111.0% 7.9% 45.2%
Cash From Investing Activities $1.391M $3.131M $3.970M
YoY Change -110.67% 9.32% 44.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000K 0.000 0.000
YoY Change -99.96% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -3.508M -835.0K -3.720M
Cash From Investing Activities 1.391M 3.131M 3.970M
Cash From Financing Activities 5.000K 0.000 0.000
Net Change In Cash -2.112M 2.296M 250.0K
YoY Change 114.63% 200.92% 1150.0%
FREE CASH FLOW
Cash From Operating Activities -$3.508M -$835.0K -$3.720M
Capital Expenditures $21.00K $4.000K -$110.0K
Free Cash Flow -$3.529M -$839.0K -$3.610M
YoY Change 2105.63% -61.35% 25.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Assets
Assets
11851000
CY2018Q4 us-gaap Assets
Assets
11228000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3238000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
942000
CY2019Q1 us-gaap Short Term Investments
ShortTermInvestments
2987000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
6122000
CY2019Q1 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
795000
CY2018Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2009000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1237000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1197000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
8257000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
10270000
CY2019Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
32000
CY2018Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
307000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
611000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
651000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3594000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
958000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5029000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4548000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2246000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1042000
CY2019Q1 bcli Deferred Grant Income
DeferredGrantIncome
511000
CY2018Q4 bcli Deferred Grant Income
DeferredGrantIncome
0
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
337000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
227000
CY2019Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
312000
CY2019Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
694000
CY2018Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
622000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8480000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6212000
CY2019Q1 us-gaap Liabilities
Liabilities
11525000
CY2018Q4 us-gaap Liabilities
Liabilities
6212000
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
11000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
98325000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
94620000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99050000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94023000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
326000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
5016000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11851000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11228000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3456000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
977000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1472000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1330000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4928000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2307000
CY2019Q1 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
99000
CY2018Q1 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-9000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5027000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2298000
CY2019Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.24
CY2018Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.12
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19047350
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20917329
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1103000
CY2018Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
276000
CY2018 us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P8M
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
59000000
CY2018Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
227000
CY2019Q1 bcli Receipts On Account Of Shares
ReceiptsOnAccountOfShares
1040000
CY2018Q4 bcli Receipts On Account Of Shares
ReceiptsOnAccountOfShares
4408000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-13948000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
917000
CY2018 bcli Stock Issued During Periodvalueexercise And Reissuance Of Warrants
StockIssuedDuringPeriodvalueexerciseAndReissuanceOfWarrants
12040000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
5016000
CY2018 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
102000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
5880000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
5016000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5027000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
312000
CY2019Q1 bcli Stock Issued During Periodvalueexercise And Reissuance Of Warrants
StockIssuedDuringPeriodvalueexerciseAndReissuanceOfWarrants
0
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
326000
CY2019Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
25000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5027000
CY2019Q1 bcli Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
511000
CY2018Q1 bcli Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
-1423000
CY2019Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1276000
CY2018Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-378000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-835000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2126000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
CY2019Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-3135000
CY2018Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2914000
CY2019Q1 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
0
CY2018Q1 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
5000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2298000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3131000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2864000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2296000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
763000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
942000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2483000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3238000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3246000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21490610
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20757816
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21490610
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20757816
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2951000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3045000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3045000
CY2019Q1 us-gaap Depreciation
Depreciation
44000
CY2018Q1 us-gaap Depreciation
Depreciation
25000
CY2019Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000
CY2018Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2019Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
312000
CY2018Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
227000
CY2019Q1 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1449000
CY2018Q1 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
116000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
481000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1837000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0
CY2019Q1 bcli Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
CY2019Q1 bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2019Q1 bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P0Y
CY2019Q1 us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P8M
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1103000
CY2017Q3 us-gaap Grants Receivable
GrantsReceivable
15912000
CY2018Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12040000
CY2018Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2458201
CY2019Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
94000
CY2018Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<table style="width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr><td style="width:56.7pt; padding:0in 0in 0in 0in;vertical-align:top;">&#160;</td><td style="width: 28.35pt; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:top;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;">D.</div></div></td><td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:top;"><div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;">Use of estimates</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin: 0px 0px 0px 85.05pt; text-align: justify; text-indent: -28.35pt; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div><div style="margin: 0px 0px 0px 85.05pt; text-align: justify; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
317000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3197000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
953000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1254000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1186000
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3393000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3045000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3045000
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001137883
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
BCLI
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21703109
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
348000

Files In Submission

Name View Source Status
0001144204-19-025310-index-headers.html Edgar Link pending
0001144204-19-025310-index.html Edgar Link pending
0001144204-19-025310.txt Edgar Link pending
0001144204-19-025310-xbrl.zip Edgar Link pending
bcli-20190331.xml Edgar Link completed
bcli-20190331.xsd Edgar Link pending
bcli-20190331_cal.xml Edgar Link unprocessable
bcli-20190331_def.xml Edgar Link unprocessable
bcli-20190331_lab.xml Edgar Link unprocessable
bcli-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv520507_10q.htm Edgar Link pending
tv520507_ex31-1.htm Edgar Link pending
tv520507_ex31-2.htm Edgar Link pending
tv520507_ex32-1.htm Edgar Link pending
tv520507_ex32-2.htm Edgar Link pending